Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Type/Product Area

Terms/Details (Date)


airPharma*

Britannia Pharmaceuticals Ltd. (UK)

airPharma will develop AP0016, a dry-powder formulation of Britannia's synthetic surfactant, Pumactant

airPharma will initiate a clinical program in respiratory indications, and assume control of the product outside the UK and Ireland; terms of the deal were not disclosed (11/9)

Affimed Therapeutics AG* (Germany)

Syngenta AG (Switzerland)

Deal to co-develop an Affimed Tandab antibody for cancer and other diseases

They will develop the molecules, which have four binding sites, under undisclosed terms (11/5)

Angiotech Pharmaceuticals Inc. (Canada; ANPI)

Boston Scientific Corp.

Boston Scientific exercised its right to exclusively license paclitaxel and other agents in the coronary vascular field

Angiotech's royalty increased by 1 percentage point, to between 6% and 11%; Boston Scientific also will pay $14M and a percentage of revenues for the right to sublicense the drug-eluting technology (11/23)

Ansata Therapeutics Inc.*

Medicis Pharmaceutical Corp.

Medicis got exclusive worldwide rights to Ansata's early stage antimicrobial peptide technology

Ansata gets $5M upon signing and about $9M in potential developmental milestone payments; additional milestones are possible; the focus is dermatology (12/14)

Ardent Pharmaceuticals Inc.*

ALZA Corp.

Option and license agreement for DPI-125, Ardent's lead candidate for treating pain

ALZA paid an initial fee for a 12-month option on exclusive rights; if exercised, Ardent would get further payments and potential milestones and royalties; it also got a co-promotion option in the U.S.; ALZA also got exclusive options to license additional analgesic compounds (11/3)

Arryx Inc.*

Haemonetics Corp.

Collaboration to develop new technology for a range of applications

Arryx gets a $5M equity investment and up to $12.5M in milestone payments, as well as royalties on sales; Haemonetics has exclusive rights in blood processing (10/29)

Artemis Pharmaceuticals GmbH (Germany; subsidiary of Exelixis Inc.; EXEL)

Schering AG (Germany)

Artemis will generate genetically engineered mouse models for use in Schering research

Terms of the deal were not disclosed (11/29)

Artemis Pharmaceuticals GmbH (Germany; subsidiary of Exelixis Inc.; EXEL)

Merck & Co. Inc.

Artemis will construct RNAi-modified genetically engineered mice for the in vivo functional analysis of selected disease-related genes

Terms of the deal were not disclosed (10/25)

BioMarin Pharmaceutical Inc. (BMRN)

Daiichi Suntory Pharma Co. Ltd. (Japan)

Deal covering Phenoptin, an investigational oral enzyme co-factor being developed for phenylketonuria

BioMarin gets access to data on the active ingredient of the product and would pay approval milestones and royalties outside Japan; Daiichi keeps rights in Japan (11/23)

BioVisioN AG* (Germany)

Novartis Pharma AG (Switzerland)

BioVisioN will evaluate clinical samples provided by Novartis using its Differential Peptide Display technology

The goal is to find and identify clinically relevant peptides; terms were not disclosed (12/9)

Cambridge Antibody Technology Group plc (UK; LSE:CAT)

AstraZeneca plc (UK)

Deal for development of monoclonal antibody drugs that includes a five-year initial phase under which they will initiate at least 25 programs; the initial focus is inflammatory disorders

They will share the $175M-plus cost of the discovery phase; AstraZeneca is investing $139M at a premium for a 19.9% stake in CAT; each firm has certain options to co-develop resulting products, or receive potential milestones and royalties; Astra-Zeneca also gets rights to co-develop existing CAT programs (11/22)

Celgene Corp. (CELG)

Various companies

Manufacturers of isotretinoin licensed patents in order to implement a new pregnancy risk-management system

The licenses were secured by Barr Pharmaceuticals Inc. and Mylan/Bertek, on behalf of Genpharm International Inc., Ranbaxy Laboratories Ltd. and F. Hoffmann-La Roche Ltd. (11/23)

Cellomics Inc.*

Becton, Dickinson & Co.

BD gets access to Cellomics' High Content Screening patent portfolio

Terms of the nonexclusive, worldwide license deal were not disclosed (11/9)

Cell Therapeutics Inc. (CTIC)

F. Hoffmann-La Roche Ltd. (Switzerland)

CTI got a worldwide license to bisplatinum compounds covered by Roche patents

Roche could earn certain milestone and royalty payments; at the same time, CTI licensed similar technology from the University of Vermont under similar terms (12/15)

Chiron Corp. (CHIR)

Laboratory Corp. of America Holdings

LabCorp got a semi-exclusive license to use hepatitis C nucleic acid-testing technology in screening plasma donations in the U.S.

As part of the deal, LabCorp agreed not to challenge the validity or enforceability of certain Chiron HCV patents; terms of the deal were not disclosed (12/3)

Chiron Corp. (CHIR)

F. Hoffmann-La Roche Ltd. (Switzerland)

Roche got a nonexclusive license to develop and sell small-molecule drugs against hepatitis C virus targets

Roche will pay up-front fees and potential milestone and royalty payments (10/26)

Ciphergen Biosystems Inc. (CIPH)

Pall Corp.

They entered a collaboration on process proteomics

The deal followed Pall's $32M acquisition of Ciphergen's BioSepra process chromatography business (11/30)

Codexis Inc. (subsidiary of Maxygen Inc.; MAXY)

Teva Pharmaceutical Industries Ltd. (Israel)

Deal to develop improved processes for the manufacturing of a marketed fermented pharmaceutical product

Codexis will use its MolecularBreeding technology in the deal, for which it will get R&D funding and potential milestone and royalty payments (12/14)

Corixa Corp. (CRXA)

GlaxoSmithKline plc (UK)

GSK is acquiring worldwide rights and responsibilities associated with Bexxar sales and development

Corixa, which made the move as part of a cost-cutting effort, will continue to get certain milestone and royalty payments; specific terms were not disclosed (12/13)

Crucell NV (the Netherlands; CRXL)

Edwards Lifesciences Corp.

Edwards got rights to use the PER.C6 cell line for R&D of gene therapeutics based on adenoviral vectors

Crucell also granted Edwards access to technical and regulatory support; terms of the nonexclusive deal were not disclosed (11/24)

DeCode Genetics Inc. (Iceland; DCGN)

F. Hoffmann-La Roche Ltd. (Switzerland)

Collaboration to develop and market phosphodiesterase 4 inhibitors for preventing and treating vascular diseases

DeCode will optimize lead compounds and begin development; the firms will share discovery and trial costs; DeCode is eligible for milestone and royalty payments (11/23)

Dynogen Pharmaceuticals Inc.*

Mitsubishi Pharma Corp. (Japan)

Dynogen acquired exclusive rights to the clinical-stage compound pumosetrag

The product (DDP733) will be developed for gastrointestinal disorders; terms of the deal were not disclosed (11/4)

Eiffel Technologies Ltd. (Australia; ASX:EIF)

Undisclosed company

Deal to evaluate Eiffel's re-engineering technology with two of the partner's oral drugs

Eiffel will apply its technology to one drug that is approved and one that is in development; terms were not disclosed (11/26)

Eiffel Technologies Ltd. (Australia; ASX:EIF)

Undisclosed U.S. company

Deal to develop an asthma treatment using Eiffel's re-engineered drugs and the partner's delivery device

Eiffel gets $0.15M up front and $0.78M in potential milestones; a license and supply deal could be signed after initial development (11/22)

Emisphere Technologies Inc. (EMIS)

Novartis Pharma AG (Switzerland)

Option and license deal on an oral form of parathyroid hormone using Emisphere's eligen delivery technology

Emisphere received $10M in exchange for a convertible note; Emisphere is eligible for milestone payments of up to $30M, plus royalties, if Novartis exercises its option on the product (12/1)

Emisphere Technologies Inc. (EMIS)

F. Hoffmann-La Roche Ltd. (Switzerland)

License deal for development of oral formulations of undisclosed compounds approved for use in the field of bone-related diseases

Emisphere gets an initial up-front fee, and milestone payments of up to $18.5M for each product developed using its eligen technology; it also would get royalties on sales (11/18)

Eurand International SpA* (Italy)

Par Pharmaceutical Inc.

Par will market Eurand's potassium chloride tablet in the U.S., where it gained approval in 3Q:04

Eurand gets an undisclosed up-front fee and a share of the profits (12/6)

ExonHit Therapeutics SA* (France)

Agilent Technologies Inc.

Deal to develop a microarray-based solution to monitor the expression of splice variants

They will combine Agilent's microarray platform and ExonHit's alternative RNA splicing technologies; terms were not disclosed (11/15)

Genstruct Inc.*

Pfizer Inc.

Genstruct will investigate mechanism-of-action and toxicity data on Pfizer compounds

They will work on a variety of research projects in a deal that continues an existing relationship; terms were not disclosed (11/8)

Genzyme Corp. (GENZ)

Wyeth

Genzyme is repurchasing the rights to Synvisc (hylan G-F 20) in the U.S. and five European countries

Genzyme will pay $121M in cash up front and sales milestones through June 2012 or up to $294M, whichever comes first; Genzyme also will offer jobs to 105 employees involved in U.S. Synvisc sales (11/4)

GTx Inc. (GTXI)

Orion Corp. (Finland)

GTx purchased all remaining rights to toremifene in the U.S. and additional rights in all other countries

GTx will pay $5.2M for the existing U.S Fareston business in metastatic breast cancer, and will continue developing its Acapodene product; Orion also will get royalties on Fareston sales (12/14)

Human Genome Sciences Inc. (HGSI)

GlaxoSmithKline plc (UK)

GSK acquired worldwide rights to the preclinical diabetes product Albugon (albumin-GLP-1)

HGS gets an up-front fee and clinical and commercial milestone payments that could total $183M, as well as additional milestones for other indications and royalties on any sales (10/26)

Ingenuity Systems*

Merck & Co. Inc.

Merck licensed the Ingenuity Pathways Analysis application

Merck can use the software and knowledge-base of biological networks at its sites worldwide under the multiyear deal (12/6)

Inpharmatica Ltd.* (UK)

Novartis Institutes for Biomedical Research

Novartis will use Inpharmatica's Chematica technology to identify molecular targets

Terms of the drug-discovery deal were not disclosed (12/13)

Inpharmatica Ltd.* (UK)

Shionogi & Co. Ltd. (Japan)

Shionogi got a nonexclusive subscription to Biopendium Online

Terms of the deal, involving protein annotation technology, were not disclosed (11/30)

Integrated BioPharma Inc. (AMEX:INB)

Fraunhofer USA Inc.

Deal to develop a flu vaccine using transient expression vectors based on plant viruses

The deal was made with IBP subsidiary INB Biotechnologies Inc.; terms were not disclosed (10/21)

ISTA Pharmaceuticals Inc. (ISTA)

Senju Pharmaceuticals Co. Ltd. (Japan)

ISTA licensed exclusive U.S. marketing rights to ecabet sodium, an eye-drop product for treating dry-eye syndrome

Senju gets an up-front and milestone payments, and royalties on any sales; ISTA will complete all U.S. development activities; it is the third product ISTA licensed from Senju (11/18)

Medarex Inc. (MEDX)

Bristol-Myers Squibb Co.

Collaboration to develop and sell MDX-010, a fully human antibody in Phase III trials for metastatic melanoma; the deal also includes MDX-1379, a gp100 peptide that might be used with MDX-010

Medarex gets $25M in cash and a $25M equity investment up front, as well as up to $205M in regulatory milestones and up to $275M in sales milestones; Medarex has an option to co-promote and share profits in the U.S., and would get royalties on other sales (11/8)

Medivir AB (Sweden; SSE: MVIR)

Tibotec Pharmaceuticals Ltd. (Belgium; unit of Johnson & Johnson)

Deal to discover and develop orally active inhibitors of the NS3/4A protease of the hepatitis C virus

Medivir gets |6.5M up front, research funding and milestone payments of up to |62M; it would keep rights in Nordic countries and would receive royalties on sales elsewhere; and it could get Nordic rights to a J&J product or additional payments (11/30)

Morphotek Inc.*

Novo Nordisk A/S (Denmark)

Deal to use Morphotek's Morphodoma technology to develop cell lines for manufacturing of antibodies

Morphotek gets an up-front payment and R&D funding to support efforts to optimize up to four products; it also is eligible for licensing fees and milestone payments on the products (12/1)

Nastech Pharmaceutical Co. Inc. (NSTK)

Par Pharmaceutical Inc.

Exclusive deal covering U.S. marketing of Nastech's calcitonin-salmon nasal spray for treating osteoporosis

Nastech gets an up-front payment, regulatory and post-approval milestones, payments for final manufactured product, and a profit-sharing arrangement (10/25)

Neurocrine Biosciences Inc. (NBIX)

Almirall Prodesfarma SA (Spain)

License agreement covering development of A2A receptor antagonists for Parkinson's disease

They will share territorial rights and registration data from their respective territories for products identified during the research term; further details were not disclosed (11/10)

Neuronova AG* (Germany)

Prestwick Chemical Inc. (France)

Prestwick will optimize a Neuronova small molecule with antidepressant properties

Prestwick will apply its medicinal chemistry platform in the deal, terms of which were not disclosed (11/5)

Norak Biosciences Inc.*

AstraZeneca plc (UK)

License deal allowing Astra-Zeneca to continue using Transfluor technology in its GPCR drug discovery program

It is the second deal between the companies; terms were not disclosed (11/3)

Novozymes A/S* (Denmark)

Solvay Pharmaceuticals BV (Belgium)

Collaboration to develop enzyme-replacement products for treating pancreatic exocrine insufficiency

Solvay will pay costs related to the development of digestive enzymes; further terms were not disclosed (11/8)

Pharmagene plc (UK; LSE:PGN)

Bayer HealthCare AG (Germany)

They replaced December 2003 deal under which Pharmagene provided validation services with a new services agreement

The initial deal was for two years; Bayer now has more flexibility in using services; also, Pharmagene got rights to evaluate certain advanced preclinical compounds from Bayer now outside of Bayer's core research interests (12/13)

Pharmasset Inc.*

F. Hoffmann-La Roche Ltd. (Switzerland)

Collaboration to develop nucleoside polymerase inhibitors for treating chronic hepatitis C virus infections

Pharmasset gets an up-front fee, R&D support and milestone payments that could total $168M for the lead compound, PSI-6130; it also would get royalties, and kept certain co-promotion rights; Roche also got options to related products, and made a $4M investment in Pharmasset (10/27)

Phytopharm plc (UK; LSE:PYM)

Unilever plc (UK)

Unilever got exclusive global rights to Phytopharm's Hoodia gordonii extract

Phytopharm will get at least $12.5M and up to $40M in the deal on the obesity-targeted extract; it also would get royalties on sales (12/15)

Plexxikon Inc.*

Wyeth

Deal to develop PLX204 and other small-molecule drugs targeting PPAR nuclear receptors for treating Type II diabetes and other metabolic disorders

Plexxikon will get more than $22M in upfront and research payments, and could earn milestone payments of up to $350M; it also gets a loan to fund its share of clinical development, and would get royalties on sales (10/28)

Procognia Ltd.* (UK)

PerkinElmer Inc.

Deal to distribute a solution for analysis of the glycosylation of proteins

They will co-market the product that combines Procognia's lectin array-based platform with PE's instrumentation (12/15)

Prometheus Laboratories Inc.*

AstraZeneca plc (UK)

Prometheus will exclusively market Entocort EC (budesonide) capsules in the U.S. starting Jan. 1 under a five-year deal

The product is approved for treating mild to moderate active Crohn's disease involving the ileum and/or the ascending colon; 2004 sales were estimated at $30M; Astra-Zeneca gets an up-front payment, royalties and potential milestone payments (12/1)

Provalis plc (UK; LSE:PRO)

Sanofi-Aventis Group (France)

Aventis Pasteur got an option to develop vaccine candidates to prevent Streptococcus pneumoniae infection

Aventis will pay an initial option fee and patent-related costs; Provalis could earn milestone and royalty payments if the 24-month option is exercised (12/13)

Purely Proteins Ltd. (UK)

Asahi-Kasei Corp. (Japan)

Collaboration to develop new methods for purifying proteins

Purely Proteins will use its ligand discovery systems in the deal, terms of which were not disclosed (12/1)

Rigel Pharmaceuticals Inc. (RIGL)

Merck & Co. Inc.

Collaboration to investigate ubiquitin ligases for treating cancer and other diseases; it is based on new Merck targets, and doesn't include Rigel's existing ligase targets

Rigel gets an initial cash payment and 2.5 years of research funding; Rigel also is eligible for preclinical and clinical milestone payments, and royalties on sales; Rigel may nominate its own targets for potential inclusion in the collaboration (11/15)

Sequella Inc.*

Sankyo Co. Ltd. (Japan)

Sequella licensed rights to Sankyo's anti-tuberculosis translocase inhibitors

Sequella got all rights in all territories in exchange for potential milestone and royalty payments (11/1)

Sequenom Inc. (SQNM)

Siemens AG (Germany)

To explore the requirements for next-generation molecular diagnostics platforms

Siemens will purchase four MassArray Compact systems as part of the deal, terms of which were not disclosed (10/26)

Triad Therapeutics Inc.*

Novartis Pharma AG (Switzerland)

Novartis acquired Triad's p38 kinase inhibitor program

Triad gets an up-front payment and up to $66M in milestone payments, as well as royalties on any sales; it could earn more as new indications are developed (12/7)

Tripos Inc. (TRPS)

Sanofi-Aventis Group (France)

Tripos will use its chemistry approach to design and synthesize compounds for Sanofi

Terms of the drug discovery deal were not disclosed (11/30)

Vaccinex Inc.*

Biocon Ltd. (India)

Partnership to discover and co-develop at least four therapeutic antibodies in the areas of cancer, inflammation and autoimmune disease

The deal combines Vaccinex's antibody discovery technology with Biocon's expertise in clinical research and manufacturing; Vaccinex will receive an equity investment in the deal; further terms were not disclosed (11/18)

Zilip-Pharma* (the Netherlands)

Bayer HealthCare AG (Germany)

Deal to develop a longer-acting form of Kogenate, Bayer's recombinant Factor VIII treatment for hemophilia A

Zilip-Pharma will apply its liposome technology to Kogenate and other Factor VIII products; Bayer supported previous studies of the technology; terms were not disclosed (11/22)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; SSE = Stockholm Stock Exchange.

No Comments